Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32082017 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL153999 | 0.84 | MAOA (0.57) | ALDH1A1KDM4ECARM1MAOAMAOB | |
| SCHEMBL31841937 | 0.84 | MAOA (0.57) | ALDH1A1KDM4ECARM1MAOAMAOB | |
| SCHEMBL2632719 | 0.80 | ALDH1A1 (0.68) | ALDH1A1CYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL8391771 | 0.80 | CYP3A4 (0.41) | ALDH1A1CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL7884784 | 0.78 | CHRNA7 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19CHRNA7 | |
| SCHEMBL30072993 | 0.78 | ALDH1A1 (0.59) | ALDH1A1CYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL23848981 | 0.77 | PRMT5 (0.42) | ALDH1A1CYP1A2CYP2D6CYP2C19NPC1 | |
| SCHEMBL38660913 | 0.77 | ALDH1A1 (0.81) | ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL14670200 | 0.77 | ALDH1A1 (0.81) | ALDH1A1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186896-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2023-05-31 | — | — | EP | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| CN-115353667-A | Method and material for reducing waste | 李蓁蓁 | 2022-11-18 | — | — | CN | disclosed |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3985000-A1 | 2,4-DISUBSTITUTED PYRIMIDINE DERIVATIVE, PREPARATION METHOD FOR SAME, AND USES THEREOF | Chengdu Zenitar Biomedical Technology Co., Ltd. (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | MANNKIND CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-10-04 | — | — | US | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| WO-2007016538-A2 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2007-02-08 | — | — | WO | disclosed |
| US-4954590-A | SUBJECTING ISOINDOLINE ISOINDOLE COMPOUND TO OXIDATIVE POLYMERIZATION; ELECTROCONDUCTIVE POLYMER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-09-04 | — | — | US | disclosed |
| US-4833231-A | Polymer having isoindole structure | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1989-05-23 | — | — | US | disclosed |
| EP-0248915-A1 | POLYMERS HAVING ISOINDOLE STRUCTURE AND PROCESS FOR THEIR PREPARATION | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232668-A1 | Orally Bioavailable Caffeic Acid Related Anticancer Drugs | STAT3, JAK2, STAT5A | ALDH1A1 970/4885CYP1A2 1213/4885CYP2D6 771/4885 |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | ALDH1A1 399/4885CYP1A2 2939/4885CYP2D6 4541/4885 |
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | ALDH1A1 2121/4885CYP1A2 2497/4885CYP2D6 1675/4885 |
| US-20070293499-A1 | Intracellular Kinase Inhibitors | PI4KB, BTK, LTK | ALDH1A1 4370/4885CYP1A2 4877/4885CYP2D6 4867/4885 |
| US-20220402926-A1 | NOVEL MACROCYCLIC SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | ALDH1A1 922/4885CYP1A2 2864/4885CYP2D6 898/4885 |
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | ALDH1A1 307/4885CYP1A2 1010/4885CYP2D6 338/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | ALDH1A1 399/4885CYP1A2 2939/4885CYP2D6 4541/4885 |
| US-11339170-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | ALDH1A1 319/4885CYP1A2 1377/4885CYP2D6 344/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | ALDH1A1 489/4885CYP1A2 3293/4885CYP2D6 2930/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | ALDH1A1 2097/4885CYP1A2 4547/4885CYP2D6 3066/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | ALDH1A1 218/4885CYP1A2 1307/4885CYP2D6 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.